ValuEngine lowered shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) from a sell rating to a strong sell rating in a report issued on Tuesday morning.
Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $7.00 target price on the stock in a research report on Tuesday, June 6th. Cowen and Company reaffirmed an outperform rating and issued a $40.00 target price on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $18.00 target price (up from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Needham & Company LLC downgraded shares of Genocea Biosciences from a buy rating to a hold rating in a research report on Tuesday. Finally, Stifel Nicolaus downgraded shares of Genocea Biosciences from a buy rating to a hold rating and dropped their target price for the company from $15.00 to $2.50 in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $10.23.
Genocea Biosciences (NASDAQ:GNCA) opened at 1.46 on Tuesday. The stock’s market capitalization is $41.79 million. The firm has a 50-day moving average of $4.75 and a 200 day moving average of $5.55. Genocea Biosciences has a 12-month low of $1.21 and a 12-month high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). On average, analysts predict that Genocea Biosciences will post ($1.92) earnings per share for the current fiscal year.
In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new stake in shares of Genocea Biosciences in the second quarter valued at about $100,000. Ameriprise Financial Inc. boosted its holdings in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 5,068 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Genocea Biosciences in the second quarter valued at about $125,000. Keybank National Association OH purchased a new stake in shares of Genocea Biosciences in the first quarter valued at about $147,000. Finally, Segantii Capital Management Ltd purchased a new stake in shares of Genocea Biosciences in the first quarter valued at about $160,000. 59.25% of the stock is currently owned by institutional investors.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
To view ValuEngine’s full report, visit ValuEngine’s official website.